“…Overall, 178,298 and 170,760 patients received mRNA-1273 and BNT162b2, respectively. Studies included mostly US populations (n=12) ( 18 , 44 , 46 , 55 – 59 , 61 , 64 , 65 , 67 ), with the remaining trials reporting data on patients from Spain (n=2) ( 45 , 62 ), Italy (n=1) ( 63 ), Singapore (n=1) ( 66 ), and multiple countries (n=1) ( 60 ). Specific at-risk and IC conditions included solid organ transplant (n=5) ( 44 , 45 , 55 , 61 , 67 ), cancer (n=5) ( 18 , 44 , 58 , 63 , 64 ), hemodialysis (n=2) ( 56 , 65 ), rheumatologic disease (n=3) ( 18 , 46 , 60 ), multiple sclerosis or other neurologic autoimmune disease (n=2) ( 57 , 66 ), inflammatory bowel disease (n=1) ( 59 ), and hematologic disorders (n=1) ( 62 ).…”